Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Novartis
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center